Serum Erythropoietin Level in Perinatal Asphyxia

Perinatal Hypoxia Clinical Trial

Official title:
Serum Erythropoietin Level for Detection of Kidney and Brain Injuries in Asphyxiated Neonates in Neonatal Intensive Care Unit.

Status Completed

Clinical Trial Summary

This study is to evaluate brain and kidney injuries in full-term neonates with perinatal asphyxia by detecting specific biomarker in blood (Erythropoietin).

Clinical Trial Description

Perinatal hypoxic-ischemic encephalopathy (HIE) is an important cause of brain injury in the newborn and can result in long-term devastating consequences. Acute kidney injury (AKI) occurs in (50 - 72%) among asphyxiated term infants. The kidney cells that make erythropoietin are sensitive to low oxygen levels in the blood that travels through the kidney. These cells make and release erythropoietin when the oxygen level is too low. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05018364
Study type	Observational
Source	Cairo University
Contact
Status	Completed
Phase
Start date	August 1, 2020
Completion date	June 15, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03407729` - Measuring Brain Activity of School Age Children
	Not yet recruiting	`NCT04913324` - Early Virtual Intervention for Infants With CP Following HIE Diagnosis	N/A